US Generics Market Continues To Seek Stability
Firms Adopt Varying Strategies To Ride Out Ongoing Turbulence In The US
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
You may also be interested in...
Upsher-Smith has strengthened its US generics portfolio with three new launches that will compete in a combined market worth nearly $102.5m.
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.
The AAM is now searching for new leadership after Chip Davis announced his resignation as president and CEO of the US off-patent industry association.